Study summary · research use only
Orforglipron in type 2 diabetes mellitus and obesity: an overview
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review (species not specified; drawing on human clinical studies) searched Scopus, PubMed/MEDLINE, and Google Scholar on orforglipron, a novel oral non-peptide GLP-1 receptor agonist. In people with type 2 diabetes mellitus (T2DM), it was associated with reductions in glycated hemoglobin (HbA1c) by up to 2.10%, weight by up to 10.1 kg, and waist circumference by up to 8.7 cm. In studies of people who were overweight or had obesity, weight loss of up to 13.0 kg was reported. In meta-analyses cited, orforglipron produced the largest weight loss among GLP-1RAs compared. Reductions in systolic blood pressure were also reported, in people with and without T2DM. Reported adverse effects included mild-to-moderate vomiting and nausea, particularly at high doses and after rapid dose escalation.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes mellitus (T2DM) and obesity. An electronic search was conducted in Scopus, PubMed/MEDLINE, and Google Scholar databases. Orforglipron is a novel oral non-peptide GLP-1RA. In T2DM individuals, it has led to reductions in glycated hemoglobin (HbA1c) by up to 2.10%, in weight by up to 10.1 kg and in waist circumference by up to 8.7 cm. In studies on overweight or obesity, a weight loss up to 13.0 kg has been reported. In meta-analyses, orforglipron was the most efficient GLP-1RA in terms of weight loss. Significant decreases in systolic blood pressure have also been found in individuals with and without T2DM. Untoward effects include mild-to-moderate vomiting and nausea, particularly in those receiving high doses and after rapid-dose escalation. Orforglipron is a promising treatment option for T2DM and overweight or obesity, in terms of glucose control and weight loss. The increased frequency of adverse events, particularly in those receiving high doses and after rapid-dose escalation, requires caution before widespread use.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.